The Science of Thermoregulation and Vasomotor Symptoms: Possible New Targets for

体温调节和血管舒缩症状的科学：可能的新目标

• 批准号: 8784849
• 负责人: PAULINE M MAKI
• 金额: $ 4.64万
• 依托单位: UNIVERSITY OF ILLINOIS AT CHICAGO
• 依托单位国家: 美国
• 财政年份: 2014
• 资助国家: 美国
• 起止时间: 2014-08-15 至 2016-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8784849
• 关键词: Address; Aging; American; Antidepressive Agents; Area; Award; Basic Science; Cancer Survivor; Cardiovascular system; Clinical; Clinical Research; Cognitive; Complementary and alternative medicine; Consensus; Data; Development; District of Columbia; Dose; Etiology; Exercise; Exercise Physiology; FDA approved; Funding; Goals; Health; Homeostasis; Hot flushes; Journals; Knowledge; Link; Medical; Medicine; Menopausal Symptom; Menopause; Meta-Analysis; National Institute on Aging; Neurobiology; Neuropharmacology; Night Sweating; North America; Omega-3 Fatty Acids; Oral; Outcome; Paroxetine; Participant; Pathway interactions; Pharmaceutical Preparations; Physiologic Thermoregulation; Physiology; Professional Organizations; Publications; Publishing; Quality of life; Randomized Clinical Trials; Recommendation; Research; Research Personnel; Research Priority; Resources; Science; Scientific Advances and Accomplishments; Scientist; Secure; Selective Serotonin Reuptake Inhibitor; Seminal; Skin; Societies; Staging; Symptoms; Temperature; Travel; United States National Institutes of Health; Vasomotor; Woman; Women' s Health; Work; Yoga; base; clinical efficacy; cognitive function; depressive symptoms; drug development; experience; healthy aging; hormone therapy; innovation; meetings; middle age; multidisciplinary; neuroimaging; neurophysiology; new therapeutic target; posters; pre-clinical research; programs; public health relevance; randomized trial; reproductive; standard care; success; symposium; web site; working group

DESCRIPTION (provided by applicant): More than 80% of women experience vasomotor symptoms (VMS; hot flashes and night sweats) during the menopausal transition. The use of hormone therapy, the standard treatment for VMS, decreased by 75% after publication of the findings from the Women's Health Initiative. The only FDA-approved nonhormonal treatment for VMS is paroxetine, a low-dose antidepressant that showed significant but modest efficacy in randomized trials. In the past decade, our understanding of the efficacy of nonhormonal therapies on VMS has increased considerably based on findings from randomized clinical trials. Unfortunately, the results from these trials show no-to-minimal efficacy, and two nonhormonal VMS medications recently failed to win FDA approval. Women therefore have very few nonhormonal treatment options for VMS. To address the continuing need for development of new nonhormonal therapies for VMS, we propose a multidisciplinary, 2-day conference, The Science of Thermoregulation and Vasomotor Symptoms: Possible New Targets for Treatment. The conference will convene a diverse group of 20 to 25 basic and clinical researchers as well as clinicians to discuss normal and aberrant thermoregulation, the neurophysiology of VMS, and new potential treatment targets. The aim of the conference is to facilitate synthesis and exchange of new data by promoting scientific exchange among experts who do not typically interact scientifically but whose work informs the others. In recent years, scientific understanding of the mechanisms involved in VMS has evolved considerably based on findings from basic science, physiology, neuroimaging, and studies of skin dynamics. The specific aims are to 1) describe current understanding of the physiology and neuropharmacology of thermoregulation and VMS; 2) describe current understanding of nonhormonal treatments for VMS; 3) review existing evidence from studies linking VMS to adverse health outcomes in women, including quality of life, cardiovascular outcomes, and cognitive function; 4) integrate new and emerging data from multiple areas of inquiry into an initial conceptual framework to better understand the causal pathway of VMS and potential avenues for new drug development. The Day 1 public symposium, open to 80 participants, will feature oral and poster presentations of recent scientific advances in thermoregulation and VMS and discussion of the implications of this new evidence for the development of nonhormonal VMS treatments. On Day 2, facilitated working groups will discuss and respond to targeted questions regarding research priorities. We offer four travel awards for new investigators. The meeting will be sponsored by The North American Menopause Society (NAMS) and will take place October 14-15, 2014, just before the 25th NAMS Annual Meeting in Washington, DC. The symposium recommendations will be presented in a special session at the NAMS meeting. A Program Planning Committee will prepare a conference summary for oral presentation at the NAMS Annual Meeting, an executive summary of the recommendations for publication in the official NAMS journal, Menopause, and a lay version to be published on the NAMS website.

描述（由申请人提供）：超过80%的女性在绝经过渡期出现血管痉挛症状（VMS;潮热和盗汗）。在妇女健康倡议的研究结果发表后，激素治疗（VMS的标准治疗）的使用减少了75%。唯一FDA批准的VMS非激素治疗是帕罗西汀，一种低剂量抗抑郁药，在随机试验中显示出显着但适度的疗效。在过去的十年中，我们对非激素疗法对VMS的疗效的理解基于随机临床试验的结果大大增加。不幸的是，这些试验的结果显示没有到最小的疗效，两种非激素类VMS药物最近未能获得FDA的批准。因此，女性对VMS的非激素治疗选择很少。为了解决持续需要开发新的非激素疗法治疗VMS，我们提出了一个多学科的，为期2天的会议，温度调节和血管紧张症状的科学：可能的治疗新靶点。会议将召集20至25名基础和临床研究人员以及临床医生组成的多元化小组，讨论正常和异常的体温调节，VMS的神经生理学以及新的潜在治疗靶点。会议的目的是通过促进专家之间的科学交流来促进新数据的综合和交流，这些专家通常不进行科学交流，但他们的工作为其他人提供了信息。近年来，基于基础科学、生理学、神经影像学和皮肤动力学研究的发现，对VMS所涉及机制的科学理解已经有了相当大的发展。具体目标是：1）描述目前对体温调节和VMS的生理学和神经药理学的理解; 2）描述目前对VMS非激素治疗的理解; 3）审查将VMS与女性不良健康结局（包括生活质量，心血管结局和认知功能）联系起来的研究的现有证据; 4）将来自多个研究领域的新数据和新兴数据整合到初始概念框架中，以更好地了解VMS的因果途径和新药开发的潜在途径。第一天的公开研讨会，向80名与会者开放，将以口头和海报介绍体温调节和VMS的最新科学进展，并讨论这一新证据对非激素VMS治疗发展的影响。在第二天，促进工作组将讨论和回答有关研究优先事项的有针对性的问题。我们为新调查员提供四项旅行奖励。该会议将由北美更年期协会（NAMS）赞助，并将于2014年10月14日至15日举行，就在华盛顿举行的第25届NAMS年会之前。专题讨论会的建议将在NAMS会议的特别会议上提出。一个计划规划委员会将准备一份会议摘要，在NAMS年会上进行口头陈述，在NAMS官方期刊《更年期》上发表建议的执行摘要，以及在NAMS网站上发表的非专业版本。